MedPath

Acute cardiometabole risico’s tijdens de behandeling met haloperidol bij ouderen.

Suspended
Conditions
ouderen, delier, antipsychoticaelderly, delirium, antipsychotics
Registration Number
NL-OMON21267
Lead Sponsor
Tergooiziekenhuizen
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Suspended
Sex
Not specified
Target Recruitment
128
Inclusion Criteria

1. Age 70 years and older admitted for hip fracture or other fall-related fractures;

2. Inclusion within 72 hours after admission;

Exclusion Criteria

1. Use of an antipsychotic agent within 90 days before admission;

2. Start or dose change in of any anticoagulants, Qtc prolongation drugs, antidiabetic drugs, antihypertensive drugs or cholesterol lowering drugs;

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. QTc- prolongation measured with holter ECG;<br /><br>2. Serum NT-proBNP, glucose, triglycerides;<br /><br>3. Closure time.
Secondary Outcome Measures
NameTimeMethod
1. QTc- prolongation measured with ECG;<br /><br>2. Serum concentration haloperidol;<br /><br>3. DDD;<br /><br>4. Total antipsychotic expose;<br /><br>5. DNA profile.
© Copyright 2025. All Rights Reserved by MedPath